Camilleri Michael, Halawi Houssam, Oduyebo Ibironke
a Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.) , Mayo Clinic , Rochester , MN, USA.
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):303-316. doi: 10.1080/17474124.2017.1288096. Epub 2017 Feb 13.
Irritable bowel syndrome (IBS) is a common condition in clinical practice. There are currently no objective tests to rule in the disease, but rather tests to rule out other diseases. Biomarkers in IBS may provide the tools needed for diagnosis, prognosis and therapy. These include identification of differences in microbial composition, immune activation, bile acid composition, colonic transit, and alteration in sensation in subgroups of IBS patients. Areas covered: Studies included in our review were chosen based on a PubMed search for 'biomarkers' and 'IBS'. We have reviewed the literature on biomarkers to appraise their accuracy, validity and whether they are actionable. We have not covered genetic associations as biomarkers in this review. Expert commentary: There is significant promise in the usefulness of biomarkers for IBS. The most promising actionable biomarkers are markers of changes in bile acid balance, such as elevated bile acid in the stool, and altered colonic transit. However, there is also potential for microbial studies and mucosal proteases as future actionable biomarkers.
肠易激综合征（IBS）是临床实践中的一种常见病症。目前尚无用于确诊该疾病的客观检测方法，而是通过检测来排除其他疾病。IBS中的生物标志物可能提供诊断、预后和治疗所需的工具。这些包括识别IBS患者亚组中微生物组成、免疫激活、胆汁酸组成、结肠转运以及感觉改变方面的差异。涵盖领域：我们综述中纳入的研究是基于在PubMed上搜索“生物标志物”和“IBS”而选择的。我们回顾了关于生物标志物的文献，以评估其准确性、有效性以及是否具有可操作性。在本综述中，我们未涉及作为生物标志物的基因关联。专家评论：生物标志物对IBS的实用性具有重大前景。最有前景的可操作生物标志物是胆汁酸平衡变化的标志物，如粪便中胆汁酸升高以及结肠转运改变。然而，微生物研究和黏膜蛋白酶作为未来可操作生物标志物也具有潜力。
